Navigation Links
Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
Date:12/20/2007

Amir Avniel, Company's CEO, Recently Completed Relocation to New York

REHOVOT, Israel, and NEW YORK, August 10 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a global leader in microRNA and RNAi, announced today it has initiated the expansion of its US operations with the relocation of Amir Avniel, Chief Executive Officer, from the company's headquarters in Rehovot, Israel, to New York. The move is intended to facilitate the expected launch of Rosetta Genomics' first products, growth through partnerships and collaborations, as well as overall corporate operations in the US. The company recently announced the expansion of its diagnostic pipeline and expects the first products to be launched in 2008.

In addition, the company announces the departure Michael French, the President of its fully owned US subsidiary - 'Rosetta Genomics Inc.', whose duties will be assumed by Mr. Avniel.

"As we move closer to the planned launch of our first diagnostic products in 2008 and to ensure the growth and expansion of our technologies, it is critical to have our senior executives based in the US," said Yoav Chelouche, Rosetta Genomics' Chairman of the Board of Directors. "Amir Avniel, as our CEO, brings valuable strategic insight, in addition to a comprehensive understanding of the development of microRNA diagnostics and therapeutics. I also would like to thank Michael French for his contribution to Rosetta Genomics."

Along with Mr. Avniel, Dalia Cohen, Executive VP will be overseeing global R&D efforts from the company's New Jersey offices.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the development of therapeutics and diagnostic products, and the timing of launch of our first diagnostic products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of Rosetta's product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Media

Alan Zachary

T: +1-(312)-944-6784

media@rosettagenomics.com

Investors

Juliane Snowden

T: +1-(212)-213-0006

investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
11. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water ... Board of Directors. Dr. Henig will bring a wealth of scientific experience in the ... the Chief Technical and Scientific Officer of four major global companies in the last ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... for all six of their healthcare job boards. As the largest network ... occupational therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com Health Network work to ...
(Date:6/22/2017)... (PRWEB) , ... June 21, 2017 , ... ... regional office in North Carolina, and engages Timothy Reinhardt to manage the new ... quality leadership at Pfizer Inc, with his most recent role as the Director ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... designating infertility as a disease, bringing new hope for prospective parents who are ... annual meeting to back the World Health Organization’s designation in hopes of changing ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):